

DAFTAR PUSTAKA

1. Tsang JKW, Liu J, Lo ACY. Vascular and neuronal protection in the developing retina: Potential therapeutic targets for retinopathy of prematurity. *Int J Mol Sci.* 2019;20(17):1-33.
2. Freitas AM, Mörschbacher R, Thorell MR, Rhoden EL. Incidence and risk factors for retinopathy of prematurity: A retrospective cohort study. *Int J Retin Vitro.* 2018;4(1):1-8.
3. Blencowe H, Lawn JE, Vazquez T, Fielder A, Gilbert C. Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. *Pediatr Res.* 2013;74(SUPPL. 1):35-49.
4. Gong Y, Fu Z, Liegl R, Chen J, Hellström A, Smith LEH. ω -3 and ω -6 long-chain PUFAs and their enzymatic metabolites in neovascular eye diseases. *Am J Clin Nutr.* 2017;106(1):16-26.
5. Heidary G, Vanderveen D, Smith LE. Retinopathy of prematurity: Current concepts in molecular pathogenesis. *Semin Ophthalmol.* 2009;24(2):77-81.
6. Rivera JC, Sapieha P, Joyal JS, et al. Understanding retinopathy of prematurity: Update on pathogenesis. *Neonatology.* 2011;100(4):343-353.
7. Vähätupa M, Järvinen TAH, Uusitalo-Järvinen H. Exploration of Oxygen-Induced Retinopathy Model to Discover New Therapeutic Drug Targets in Retinopathies. *Front Pharmacol.* 2020;11(June):1-12.
8. Kim C, D'Amore P, Connor K. Revisiting the mouse model of oxygen-induced retinopathy. *Eye Brain.* 2016 May;67.
9. Vayalthrikkovil S, Bashir RA, Rabi Y, et al. Parenteral Fish-Oil Lipid Emulsions in the Prevention of Severe Retinopathy of Prematurity: A Systematic Review and Meta-Analysis. *Am J Perinatol.* 2017;34(7):705-

715.

10. Liu Q, Wu D, Ni N, Ren H, Luo C, He C, et al. Omega-3 Polyunsaturated Fatty Acids Protect Neural Progenitor Cells against Oxidative Injury. *Mar Drugs*. 2014 Apr 29;12(5):2341–56.
11. Hellström A, Nilsson AK, Wackernagel D, et al. Effect of Enteral Lipid Supplement on Severe Retinopathy of Prematurity: A Randomized Clinical Trial. *JAMA Pediatric*. 2021;175(4):359-367.
12. Nobre MEP, Correia AO, Mendonça FNM, et al. Omega-3 Fatty Acids: Possible Neuroprotective Mechanisms in the Model of Global Ischemia in Rats. *J Nutr Metab*. 2016;2016.
13. Marselina M, Marselina M. Pengaruh Pemberian Omega 3 terhadap Densitas Sel Ganglion Retina pada Tikus Model Neuropati Optik Toksik Metanol. Oleh : Published online 2018.
14. Rapuano CJ, Stout TJ, McCannel CA. Disorder of the retina and vitreous. Pediatric ophthalmology and strabismus. San Fransisco: *American Academy of Ophthalmology*; 2021. p 325–335
15. Azad R, Gilbert C, Gangwe AB, et al. Retinopathy of prematurity: How to prevent the third epidemics in developing countries. *Asia-Pacific J Ophthalmol*. 2020;9(5):440-448.
16. Kim SJ, Port AD, Swan R, Campbell JP, Chan RVP, Chiang MF. Retinopathy of prematurity: a review of risk factors and their clinical significance. *Surv Ophthalmol*. 2018;63(5):618-637.
17. Chandra P, Chawla D, Deorari AK, et al. Screening and Management of Retinopathy of Prematurity. *J Neonatol*. 2020;34(1-2):63-82.
18. Jousseaume AM, Gardner TW, Kirchhof B, Ryan SJ. *Retinal Vascular Disease*. Springer-Verlag Berlin Heidelberg; 2007.
19. Liu CH, Wang Z, Sun Y, Chen J. Animal models of ocular angiogenesis: From development to pathologies. *FASEB J*. 2017;31(11):4665-4681.
20. Al-Shabrawey M, Elsherbiny M, Nussbaum J, Othman A, Megyerdi S, Tawfik A. Targeting neovascularization in ischemic retinopathy: Recent advances. *Expert Rev Ophthalmol*. 2013;8(3):267-286.

21. Dorfman AL. Oxygen induced retinopathy in the neonatal rat: The effects of age, strain and therapeutic intervention on retinal structure and function. *McGill Univ*. Published online 2009.
22. Aikawa H, Noro M. Low incidence of sight-threatening retinopathy of prematurity in infants born before 28 weeks gestation at a neonatal intensive care unit in Japan. *Tohoku J Exp Med*. 2013;230(3):185-190.
23. Mezu-ndubuisi OJ, Macke EL, Kalavacherla R, Nwaba AA, Suscha A. Long-term evaluation of retinal morphology and function in a mouse model of oxygen-induced retinopathy. *Mol Vis*. 2020;26:257-276.
24. Gupta MP, Herzlich AA, Sauer T, Chan CC. Retinal anatomy and pathology. *Dev Ophthalmol*. 2016;55:7-17.
25. Fleming I. New Lipid Mediators in Retinal Angiogenesis and Retinopathy. *Front Pharmacol*. 2019;10.
26. Kumar VH. Pathogenesis and Management of Retinopathy of Prematurity in Premature Infants. *Pediatr Neonatal Nurs - Open J*. 2015;2(2):62-69.
27. Malamas A, Chranioti A, Tsakalidis C, Dimitrakos SA, Mataftsi A. The omega-3 and retinopathy of prematurity relationship. *Int J Ophthalmol*. 2017;10(2):300-305.
28. Fu Z, Gong Y, Löfqvist C, Hellström A, Smith LEH. Review: Adiponectin in retinopathy. *Biochim Biophys Acta - Mol Basis Dis*. 2016;1862(8):1392-1400.
29. Tomita Y, Usui-Ouchi A, Nilsson AK, et al. Metabolism in retinopathy of prematurity. *Life*. 2021;11(11):1-20.
30. El-atawi K, Alansari N, Elhalik M, Abdelsamed A, Mahfouz R. Management of retinopathy of prematurity: an updated review. 2022;12(1):24-29.
31. Dewi PK, Cahyono M, Prihatningtias R, Ekowati L, Wildan A. The Effect of Glutathione on Serum Malondialdehyde (MDA) Level in Retinopathy of Prematurity Rat Models. *J Biomed Transl Res*. 2020;6(3):86-88.
32. Holmström GE, Hellström A, Jakobsson PG, Lundgren P, Tornqvist K, Wallin A. Swedish national register for retinopathy of prematurity

- (SWEDROP) and the evaluation of screening in Sweden. *Arch Ophthalmol*. 2012;130(11):1418-1424.
33. Siswanto JE, Bos AF, Dijk PH, et al. Multicentre survey of retinopathy of prematurity in Indonesia. *BMJ Paediatr Open*. 2021;5(1).
 34. Holmström G, Hellström A, Jakobsson P, Lundgren P, Tornqvist K, Wallin A. Evaluation of new guidelines for ROP screening in Sweden using SWEDROP - A national quality register. *Acta Ophthalmol*. 2015;93(3):265-268.
 35. Edy Siswanto J, Sauer PJJ. Retinopathy of prematurity in Indonesia: Incidence and risk factors. *J Neonatal Perinatal Med*. 2017;10(1):85-90.
 36. Hellström A, Smith LEH, Dammann O. Retinopathy of prematurity. *Lancet*. 2013;382(9902):1445-1457.
 37. Mataftsi A, Dimitrakos SA, Adams GGW. Mediators involved in retinopathy of prematurity and emerging therapeutic targets. *Early Hum Dev*. 2011;87(10):683-690.
 38. Fleck BW. Management of retinopathy of prematurity. *Arch Dis Child Fetal Neonatal Ed*. 2013;98(5):454-457.
 39. Connor KM, Krah NM, Dennison RJ, et al. Quantification of oxygen-induced retinopathy in the mouse: A model of vessel loss, vessel regrowth and pathological angiogenesis. *Nat Protoc*. 2009;4(11):1565-1573.
 40. Spandau U, Kim SJ. *Pediatric Retinal Vascular Diseases From Angiography to Vitrectomy*. Springer Nature Switzerland AG; 2019.
 41. Fu Z, Lofqvist CA, Shao Z, et al. Dietary ω -3 polyunsaturated fatty acids decrease retinal neovascularization by adipose-endoplasmic reticulum stress reduction to increase adiponectin. *Am J Clin Nutr*. 2015;101(4):879-888.
 42. Jefferies AL. Retinopathy of prematurity - Screening and management. *Can Paediatr Soc*. 2016;21(2):101-104.
 43. Siswanto JE, Dijk PH, Bos AF, et al. How to prevent ROP in preterm infants in Indonesia? *Heal Sci Reports*. 2021;4(1):1-10.
 44. Chen J, Stahl A, Hellstrom A, Smith LE. Current update on retinopathy of

- prematurity: screening and treatment. *Curr Opin Pediatr.* 2011;23(2):173-178.
45. Silva RA, Moshfeghi DM. Interventions in retinopathy of prematurity. *Neoreviews.* 2012;13(8).
 46. Dai C, Webster KA, Bhatt A, Tian H, Su G, Li W. Concurrent physiological and pathological angiogenesis in retinopathy of prematurity and emerging therapies. *Int J Mol Sci.* 2021;22(9).
 47. Wu C, Löfqvist C, Smith LEH, VanderVeen DK, Hellström A. Importance of early postnatal weight gain for normal retinal angiogenesis in very preterm infants: A multicenter study analyzing weight velocity deviations for the prediction of retinopathy of prematurity. *Arch Ophthalmol.* 2012;130(8):992-999.
 48. Shah PK. Retinopathy of prematurity: Past, present and future. *World J Clin Pediatr.* 2016;5(1):35.
 49. Owen LA, Morrison MA, Hoffman RO, Yoder BA, DeAngelis MM. Retinopathy of prematurity: A comprehensive risk analysis for prevention and prediction of disease. *PLoS One.* 2017;12(2):1-14.
 50. Cayabyab R, Ramanathan R. Retinopathy of Prematurity: Therapeutic Strategies Based on Pathophysiology. *Neonatology.* 2016;109(4):369-376.
 51. Sternberg P, Durrani AK. Evolving Concepts in the Management of Retinopathy of Prematurity. *Am J Ophthalmol.* 2018;186:xxiii-xxxii.
 52. Kusaka S. Current concepts and techniques of vitrectomy for retinopathy of prematurity. *Taiwan J Ophthalmol.* 2018;8(4):216.
 53. Couroucli XI. Oxidative stress in the retina: Implications for retinopathy of prematurity. *Curr Opin Toxicol.* Published online 2017:1-34.
 54. O'Shea KM, Khairallah RJ, Sparagna GC, Xu W, Hecker PA, Robillard-Frayne I, et al. Dietary ω -3 fatty acids alter cardiac mitochondrial phospholipid composition and delay Ca^{2+} -induced permeability transition. *J Mol Cell Cardiol.* 2009 Dec;47(6):819-27.
 55. Heiduschka P, Plagemann T, Li L, Alex AF, Eter N. Different effects of various anti-angiogenic treatments in an experimental mouse model of

- retinopathy of prematurity. *Clin Exp Ophthalmol*. 2019;47(1):79-87.
56. Garg U, Jain A, Singla P, Beri S, Garg R, Saili A. Free radical status in retinopathy of prematurity. *Indian J Clin Biochem*. 2012;27(2):196-199.
 57. Rustam R, Sayuti K, Hendriati. Perbandingan Hispatologi *Neovascular Tuft* pada Retina Tikus yang Mengalami *Oxygen-Induced Retinopathy* dengan dan tanpa Pemberian L-Carnitine. *Maj Kedokt Bandung*. 2018;50(4):202-207.
 58. Graziosi A, Perrotta M, Russo D, et al. Oxidative stress markers and the retinopathy of prematurity. *J Clin Med*. 2020;9(9):1-18.
 59. Scott A, Fruttiger M. Oxygen-induced retinopathy: A model for vascular pathology in the retina. *Eye*. 2010;24(3):416-421.
 60. Kim YW, Byzova T V. Oxidative stress in angiogenesis and vascular disease. *Blood*. 2014;123(5):625-631.
 61. Perrone S, Vezzosi P, Longini M, et al. Biomarkers of oxidative stress in babies at high risk for retinopathy of prematurity. *Front Biosci EI*. Published online 2009:547-552.
 62. Grossniklaus HE, Kang SJ, Berglin L. Animal models of choroidal and retinal neovascularization. *Prog Retin Eye Res*. 2010;29(6):500-519.
 63. Wu W, Lam W. *A Quick Guide to Pediatric Retina*.; 2021.
 64. Hellström A, Pivodic A, Gränse L, et al. Association of *Docosahexaenoic Acid and Arachidonic Acid Serum Levels* with Retinopathy of Prematurity in Preterm Infants. *JAMA Netw Open*. 2021;4(10):1-12.
 65. Elmasry K, Ibrahim AS, Abdulmoneim S, Al-Shabrawey M. Bioactive lipids and pathological retinal angiogenesis. *Br J Pharmacol*. 2019;176(1):93-109.
 66. Löfqvist CA, Najm S, Hellgren G, et al. Association of retinopathy of prematurity with low levels of arachidonic acid a secondary analysis of a randomized clinical trial. *JAMA Ophthalmol*. 2018;136(3):271-277.
 67. Chan C-C. *Animal Models of Ophthalmic Disease*. Springer International Publishing; 2016.
 68. Stahl A, Connor KM, Sapieha P, et al. The mouse retina as an angiogenesis

- model. *Investig Ophthalmol Vis Sci*. 2010;51(6):2813-2826.
69. Sapiaha P, Chen J, Stahl A, et al. Omega-3 polyunsaturated fatty acids preserve retinal function in type 2 diabetic mice. *Nutr Diabetes*. 2012;2(JULY):36-39.
 70. Kulkarni A, Zhao A, Yang B, Zhang Y, Linderborg KM. Tissue-Specific Content of Polyunsaturated Fatty Acids in (n-3) Deficiency State of Rats. *Foods*. 2022;11(2):1-16.
 71. Chamidah A, Wicaksono A. Pembuatan Konsentrat Omega-3 dari Minyak Hati Hiu Botol dengan Metode Kristalisasi Urea. *J Perikan Univ Gadjah Mada*. 2021;23(2):119.
 72. Weylandt KH, Serini S, Chen YQ, et al. Omega-3 polyunsaturated fatty acids: The way forward in times of mixed evidence. *Biomed Res Int*. 2015;2015.
 73. Das U. Pathological retinal angiogenesis and polyunsaturated fatty acids. *Crit Rev Food Sci Nutr*. 2008;19(6):44-49.
 74. Najm S, Löfqvist C, Hellgren G, et al. Effects of a lipid emulsion containing fish oil on polyunsaturated fatty acid profiles, growth and morbidities in extremely premature infants: A randomized controlled trial. *Clin Nutr ESPEN*. 2017;20:17-23.
 75. Fu Z, Yan W, Chen CT, et al. Omega-3/Omega-6 Long-Chain Fatty Acid Imbalance in Phase I Retinopathy of Prematurity. *Nutrients*. 2022;14(7).
 76. Aranda J V., Qu J, Valencia GB, Beharry KD. Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity. *Semin Perinatol*. 2019;43(6):360-366.
 77. SanGiovanni JP, Chew EY. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. *Prog Retin Eye Res*. 2005;24(1):87-138.
 78. Elizabeth Hartnett M. The prematurity of recommending particular polyunsaturated fatty acid supplements for retinopathy of prematurity. *JAMA Ophthalmol*. 2018;136(3):277-278.
 79. Connor KM, Sangiovanni JP, Lofqvist C, et al. Increased dietary intake of

ω -3-polyunsaturated fatty acids reduces pathological retinal angiogenesis.

Nat Med. 2007;13(7):868-873.

80. Tang H, Zhu X, Gong C, Liu H, Liu F. Protective effects and mechanisms of omega-3 polyunsaturated fatty acid on intestinal injury and macrophage polarization in peritoneal dialysis rats. *Nephrology.* 2019;24(10):1081-1089.
81. Wang S, Ji L, Li L, Li J. Oxidative stress, autophagy and pyroptosis in the neovascularization of oxygen-induced retinopathy in mice. *Mol Med Rep.* 2018 Dec 13; 927-934.

